Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026623 · ClinicalTrials.gov registry record · Phase 1
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01026623: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01026623 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026623, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may kill more tumor cells.
Interventions
- OTHER Diagnostic Laboratory Biomarker Analysis
- DRUG Temsirolimus
- BIOLOGICAL Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026623
The ClinicalTrials.gov registry entry for NCT01026623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Diagnostic Laboratory Biomarker Analysis is the first listed.
NCT01026623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026623 about?
NCT01026623 is a clinical study titled "Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer". This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor...
What is the current status of trial NCT01026623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01026623?
The interventions under investigation include: Diagnostic Laboratory Biomarker Analysis (OTHER), Temsirolimus (DRUG), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01026623?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.